NOW
ServiceNow, Inc.
1.5%
-24.4%
$124.34
$94.02
Why This Position Exists
Position is -24.4% from entry but the thesis caveats have NOT triggered: DOJ investigation remains unresolved without adverse action (base case expected), Armis deal remains on track for H2 2026 close with no collapse reported, and Q1 2026 earnings have not yet been reported (scheduled April 22, 2026, seven days away). The decline is narrative-driven, crystallized by a UBS downgrade on April 10, 2026 (Buy to Neutral, PT $170 to $100) citing AI disruption concerns that ServiceNow's workflow automation revenue is at risk from autonomous AI agents — the exact cannibalization narrative the Myth Meter flagged as DISCONNECTED from operational data. Holding through Q1 2026 earnings is the correct posture: the earnings print will resolve two active markets (now-q1-2026-organic-crpo-growth, now-q1-2026-revenue-growth) and provide the first real test of the thesis caveat.
Trigger: Monthly portfolio review 2026-04-15 flagged NOW for -24.4% drawdown vs entry. Investigation found UBS downgrade on April 10, 2026 (PT $170 to $100) plus broad AI-disruption narrative intensification as proximate cause. No thesis caveat has triggered: DOJ unresolved, Armis on track, Q1 2026 earnings not yet reported (April 22).
Key Market Signals
Committee Verdict
DEFER until Q1 2026 earnings on April 22 (7 days). The Portfolio Analyst correctly identified that no thesis caveat has formally triggered: DOJ remains unresolved-but-not-adverse (base case), Armis deal is on track per the Dec 2025 announcement for H2 2026 close, and Q1 earnings have not yet printed. The Risk Manager's Kelly computation produces a ~2.1% target versus current 1.51% — technically supporting an ADD — but correctly identified that adding before a binary catalyst violates timing discipline. The Devil's Advocate verdict of thesis-fragile is the decisive input: the UBS downgrade on April 10 (PT $170 to $100) crystallizes a structural AI-substitution bear case that the thesis acknowledged as a 3-5 year risk the market is now pricing as near-term, and company-guided Q1 subscription revenue growth of 18.5-19% sits BELOW the >19% thesis market threshold — meaning even a guide-meet is a thesis-negative print. The -15% mandatory review trigger from the original committee has been breached at -24%; the committee chair rules that the Q1 earnings print IS the reassessment event, and closing the week before a known catalyst locks in the drawdown without the information that would justify the action. Holding through April 22 with a firm contingent close-or-reassess commitment is the disciplined call.
Devil's Advocate
mixedVerdict is thesis-fragile, not thesis-robust, because the core assumption (narrative will converge to operational reality within 6-12 months) is now contested by a structural long-horizon bear case that the Q1 print cannot fully resolve. That said, the devil's advocate does NOT recommend close at this moment — closing the position the week before an earnings catalyst with known guidance sitting right at the thesis threshold is poor timing and locks in the drawdown without waiting for the information. The honest call is: hold through April 22, then make a hard reassessment. If Q1 beats and stock stays down, the thesis is VALIDATED (operational reality confirmed but narrative unchanged — dangerous signal). If Q1 misses or guides down, close immediately. The -15% mandatory-review trigger from the original committee has already been breached at -24%; this review is overdue and Q1 should be the final test.
Monitoring Triggers
• MANDATORY reassessment within 48 hours of Q1 2026 earnings release (April 22, 2026) — run /post-earnings-update followed by /portfolio-evaluate
• Immediate close if Q1 subscription revenue growth prints below 18% CC OR full-year 2026 guide is lowered below the current 19.5-20% range
• Immediate close if any Armis-related financing or antitrust setback is announced before close
• Immediate close if DOJ revolving-door matter escalates beyond settlement/declination to debarment proceedings
• Reassessment if Now Assist ACV trajectory update (either at Q1 call or mid-quarter disclosure) shows deceleration from the doubling pace that underpins the 70% $1B-ACV market
• Reassessment if position drawdown reaches -35% (another -15% from current) regardless of thesis caveat status — pure risk-discipline stop
• Reassessment if Moveworks DOJ antitrust second-request matter surfaces adverse developments (divestiture requirement or block)
Position Details
Mar 7, 2026
17
price-below-value
MEDIUM
Technology
1
Trade History
| Date | Action | Shares | Price | Weight | Rationale |
|---|---|---|---|---|---|
| Mar 7, 2026 | OPEN | 17 | $124.34 | 0.0% → 2.1% | Committee approved OPEN with modification. MEDIUM confidence price-below-value thesis with 8 active markets and 0.91-0.97 model agreement. Quarter-Kelly sizing at 2.1% — formula narrowly clears 2.0% minimum. Analyst's 3.0% override denied; Risk Manager's formula output accepted. Three conditions: no ADD until primary catalyst resolves, re-evaluate if Q1 revenue < 17% CC, run Black Swan Beacon before scaling. |
Full Committee Transcripts (2)
Complete 4-step discourse records — expand each step to see the full reasoning from analyst, risk manager, devil's advocate, and committee chair.